Oncolytic Virus Therapy Market Report 2026

The oncolytic virus therapy market size has grown exponentially in recent years. It will grow from $0.23 billion in 2025 to $0.29 billion in 2026 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to development of hsv- and adenovirus-based oncolytic therapies, early clinical trials in melanoma and breast cancer, growing interest from cancer research institutes, increasing government funding for virotherapy research, rising collaborations between biotech companies and academic institutions.

The oncolytic virus therapy market size is expected to see exponential growth in the next few years. It will grow to $0.68 billion in 2030 at a compound annual growth rate (CAGR) of 23.7%. The growth in the forecast period can be attributed to rising demand for genetically engineered oncolytic viruses, increasing adoption in lung, prostate, and brain cancers, growth of specialty clinics and hospitals offering virotherapy, rising investment in combination and emerging virus therapies, expansion of clinical trial infrastructure in emerging markets. Major trends in the forecast period include rising adoption of ai and big data in oncolytic virus research, increasing use of genomics and precision medicine for therapy design, growing implementation of digital platforms for clinical trial monitoring, rising automation in virus production and quality assurance, increasing iot-based monitoring of virus storage and distribution.

The rising prevalence of cancer is expected to drive the growth of the oncolytic virus therapy market in the coming years. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Oncolytic virus therapy provides a dual mechanism of action by selectively targeting and destroying cancer cells while stimulating an immune response against the tumor, offering a promising approach for effective cancer treatment. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050 there would be over 35 million new cancer cases, representing a 77% increase compared to an estimated 20 million cases in 2022. Consequently, the increasing prevalence of cancer is fueling growth in the oncolytic virus therapy market.

Key companies in the oncolytic virus therapy market are focusing on securing regulatory approvals to accelerate the introduction of innovative cancer therapies. Regulatory approvals involve the evaluation and authorization of medical products, including drugs, biologics, and medical devices, by health authorities for market use. For instance, in March 2024, ImmVira, a China-based biotechnology company, received Fast Track designation from the U.S. FDA for its oncolytic virus therapy, MVR-T3011 IT. This therapy is intended for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have experienced disease progression after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. The designation is designed to expedite development and review for treatments addressing serious conditions with unmet medical needs.

In February 2025, UroGen Pharma Ltd., a US-Israel-based biotechnology company, acquired assets related to the oncolytic virus ICVB-1042 from IconOVir Bio, Inc., for an undisclosed amount. Through this acquisition, UroGen aims to expand its oncolytic virus therapy pipeline and enhance its technological capabilities in immunotherapy, particularly for bladder cancer and other locally treated malignancies. IconOVir Bio is a US-based company developing next-generation oncolytic viruses, including ICVB-1042, engineered to selectively kill cancer cells and trigger immune responses.

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncolytic virus therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oncolytic virus therapy market by increasing costs of viral vectors, lab reagents, and specialized equipment, affecting hospitals, specialty clinics, and cancer research institutes mainly in north america, europe, and asia-pacific. While tariffs raise operational expenses, they also encourage local production, domestic manufacturing investment, and supply chain diversification, strengthening resilience and reducing dependency on imports.

The oncolytic virus therapy market research report is one of a series of new reports that provides oncolytic virus therapy market statistics, including oncolytic virus therapy industry global market size, regional shares, competitors with a oncolytic virus therapy market share, detailed oncolytic virus therapy market segments, market trends and opportunities, and any further data you may need to thrive in the oncolytic virus therapy industry. This oncolytic virus therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oncolytic virus therapy, also known as virotherapy, is a cancer treatment that employs viruses to target and kill cancer cells in the body. The primary goal of this therapy is to use viruses - either genetically modified or naturally occurring - that can selectively infect and replicate within cancer cells while leaving healthy cells unharmed.

The main types of oncolytic virus therapy include HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), and others. HSV-based oncolytic virus therapy uses the herpes simplex virus (HSV) as the treatment platform. The virus types include both genetically engineered oncolytic viruses and wild-type oncolytic viruses. These therapies are applied in treating cancers such as breast cancer, lung cancer, prostate cancer, melanoma, brain tumors, and blood cancers, and are utilized by end users including hospitals, specialty clinics, and cancer research institutes.

The oncolytic virus therapy market includes revenues earned by entities by providing seneca valley virus (SVV), semliki forest virus (SFV), vesicular stomatitis virus (VSV), and sindbis virus (SBV). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.